A Cationic [60] Fullerene Derivative Reduces Invasion and Migration of HT-29 CRC Cells in Vitro at Dose Free of Significant Effects on Cell Survival

Nano-Micro Letters

Volumn 6, Issue 2, 2014, Pages 163-168

  Lucafò, Marianna ^a   Pelillo, Chiara ^a   Carini, Marco ^a   Da Ros, Tatiana ^a   Prato, Maurizio ^a   Sava, Gianni ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Anti metastatic drug; Cancer; Fullerene; Nanomedicine

Indexed keywords

BEHAVIORAL RESEARCH; CELL ADHESION; CELL CULTURE; DISEASES; DRUG DELIVERY; FULLERENES; MEDICAL NANOTECHNOLOGY; PHOTOSENSITIZERS;

ANTI-METASTATIC DRUG; CANCER; CELLULAR BEHAVIORS; COLORECTAL CANCER; COLORECTAL CANCER CELL; MATRIX METALLOPROTEINASES; PHYSIOLOGICAL FUNCTIONS; [60]FULLERENE DERIVATIVES;

CELLS;

EID: 84958747957     PISSN: 23116706     EISSN: 21505551     Source Type: Journal    
DOI: 10.1007/BF03353780     Document Type: Article

References (25)

1. A. Jemal, R. Siegel, J. Xu and E. Ward, “Cancer statistics, 2010”, CA Cancer J. Clin. 60(5), 277–300 (2010). http://dx.doi.org/10.3322/caac.20073
2. J. M. Davies and R. M. Goldberg, “Treatment of metastatic colorectal cancer”, Semin. Oncol. 38(4), 552–60 (2011). http://dx.doi.org/10.1053/j.seminoncol.2011.05.009
3. K. K. Jain, “Nanotechnology in clinical laboratory diagnostics”, Clin. Chim. Acta 358 (1–2), 37–54 (2005). http://dx.doi.org/10.1016/j.cccn.2005.03.014
4. P. Chaudhuri, R. Harfouche, S. Soni, D. M. Hentschel, and S. Sengupta, “Shape effect of carbon nanovectors on angiogenesis”, ACS Nano 4(1), 574–82 (2010). http://dx.doi.org/10.1021/nn901465h
5. M. Grodzik, E. Sawosz, M. Wierzbicki, P. Orlowski, A. Hotowy, T. Niemiec, M. Szmidt, K. Mitura and A. Chwalibog, “Nanoparticles of carbon allotropes inhibit glioblastoma multiforme angiogenesis in ovo”, Int. J. Nanomed. 6, 3041–3048 (2011). http://dx.doi.org/10.2147/IJN.S25528
6. M. Wierzbicki, E. Sawosz, M. Grodzik, M. Prasek, S. Jaworski and A. Chwalibog “Comparison of antiangiogenic properties of pristine carbon nanoparticles”, Nanoscale Res. Lett. 8(1), 195 (2013). http://dx.doi.org/10.1186/1556-276X-8-195
7. S. V. Prylutska, A. P. Burlaka, Y. I. Prylutskyy, U. Ritter and P. Scharff, “Pristine C(60) fullerenes inhibit the rate of tumor growth and metastasis”, Exp Oncol 33(3), 162–164 (2011).
8. C. Chen, G. Xing, J. Wang, Y. Zhao, B. Li, J. Tang, G. Jia, T. Wang, J. Sun, L. Xing, H. Yuan, Y. Gao, H. Meng, Z. Chen, F. Zhao, Z. Chai and X. Fang, “Multihydroxylated [Gd@C82(OH)22]n nanoparticles: Antineoplastic activity of high efficiency and low toxi-city”, Nano Lett. 5(10), 2050–2057 (2005). http://dx.doi.org/10.1021/nl051624b
9. M. Lucafò, S. Pacor, C. Fabbro, T. Da Ros, S. Zorzet, M. Prato and G. Sava, “Study of a potential drug delivery system based on carbon nanoparticles: Effects of fullerene derivatives in MCF7 mammary carcinoma cells”, J. Nanopart. Res. 14, 1–13 (2012). http://dx.doi.org/10.1007/s11051-012-0830-8
10. M. Lucafò, M. Gerdol, A. Pallavicini, S. Pacor, S. Zorzet, T. Da Ros, M. Prato and G. Sava, “Profiling the molecular mechanism of fullerene cytotoxicity on tumorcells by RNA-seq”, Toxicology 314(1), 183–192 (2013). http://dx.doi.org/10.1016/j.tox.2013.10.001
11. K. Kordatos, T. Da Ros, S. Bosi, E. Vazquez, M. Bergamin, C. Cusan, F. Pellarini, V. Tomberli, B. Baiti, D. Pantarotto, V. Georgakilas, G. Spalluto and M. Prato, “Novel versatile fullerene synthons”, J. Org. Chem. 66, 4915–4920 (2001). http://dx.doi.org/10.1021/jo015608k
12. A. Albini, Y. Iwamoto, H. K. Kleinman, G. R. Martin, S. A. Aaronson, J. M. Kozlowski and R. N. McEwan, “A rapid in vitro assay for quantitating the invasive potential of tumor cells”, Cancer Res. 47(12), 3239–45 (1987).
13. P. Provenzano and P. J. Keely, “Mechanical signaling through the cytoskeleton regulates cell proliferation by coordinated focal adhesion and Rho GTPase signalling”, J. Cell Sci. 124 (Pt8), 1195–1205 (2001). http://dx.doi.org/10.1242/jcs.067009
14. F. G. Giancotti and E. Ruoslahti, “Integrin signaling”, Science 285(5430), 1028–1032 (1999). http://dx.doi.org/10.1126/science.285.5430.1028
15. J. D. Hood and D. A. Cheresh, “Role of integrins in cell invasion and migration”, Nature Rev. Cancer 2(2), 91–100 (2002). http://dx.doi.org/10.1038/nrc727
16. F. Aoudjit and K. Vuori, “Integrin signaling in cancer cell survival and chemoresistance”, Chemother. Res. Pract. 1-16 (2012). http://dx.doi.org/10.1155/2012/283181
17. M. Millard, S. Odde and N. Neamati, “Integrin targeted therapeutics”, Theranostics 1, 154–188 (2011). http://dx.doi.org/10.7150/thno/v01p0154
18. S. Hernandez-Barrantes, M. Bernardo, M. Toth, and R. Fridman, “Regulation of membrane type-matrix metalloproteinases”, Semin. Cancer Biol. 12(2), 131–138 (2002). http://dx.doi.org/10.1006/scbi.2001.0421
19. H. Sato, T. Takino, Y. Okada, J. Cao, A. Shinagawa, E. Yamamoto, and M. Seiki, “A matrix metalloproteinase expressed on the surface of invasive tumour cells”, Nature 370(6484), 61–65 (1994). http://dx.doi.org/10.1038/370061a0
20. A. Y. Strongin, B. L. Marmer, G. A. Grant and G. I. Goldberg “Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2”, J. Biol. Chem. 268(19), 14033–14039 (1993).
21. Q. Nguyen, F. Willenbrock, M. I. Cockett, M. O’Shea, A. J. Docherty and G. Murphy, “Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A”, Biochem. 33(8), 2089–2095 (1994). http://dx.doi.org/10.1021/bi00174a015
22. M. Bernardo and R. Fridman, “TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP”, Biochem. J. 374 (Pt3), 739–745 (2003). http://dx.doi.org/10.1042/BJ20030557
23. P. Vempati, E. D. Karagiannis and A. S. Popel “A Biochemical Model of Matrix Metalloproteinase 9 Activation and Inhibition”, J. Biol. Chem. 282(52), 37585–37596 (2007). http://dx.doi.org/10.1074/jbc.M611500200
24. H. Kolkenbrock, D. Orgel, A. Hecker-Kia, W Noack, N. Ulbrich “The complex between a tissue inhibitor of metalloproteinases (TIMP-2) and 72-kDa progelatinase is a metalloproteinase inhibitor”, Eur. J. Biochem. 198(3), 775–781 (1991). http://dx.doi.org/10.1111/j.1432-1033.1991.tb16080.x
25. N. Fujimoto, R. V. Ward, T. Shinya, K. Iwata, Y. Yamashita and T. Hayakawa, “Interaction between tissue inhibitor of metalloproteinases-2 and progelatinase A: immunoreactivity analyses”, Biochem. J. 313 (Pt3), 827–833 (1996).